Back to top
more

Agios Pharmaceuticals (AGIO)

(Real Time Quote from BATS)

$52.64 USD

52.64
385,969

+1.05 (2.04%)

Updated Nov 7, 2024 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down

by Zacks Equity Research

Agios' third-quarter 2024 earnings miss estimates while revenues match the same. Shares fall.

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how ADC Therapeutics SA (ADCT) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

Agios Pharmaceuticals (AGIO) Misses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -74.84% and 4.29%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Agios (AGIO) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Agios (AGIO) stock based on the movements in the options market lately.

FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer

by Zacks Equity Research

The FDA bestows an orphan drug designation to Agios' PK activator, tebapivat, for treating myelodysplastic syndromes.

Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?

by Zacks Equity Research

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

by Zacks Equity Research

Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.

Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.96% and 8.66%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Quanterix Corporation (QTRX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Quanterix (QTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals (AGIO) Surges 6.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Agios (AGIO) Up 21% on Upbeat Data From 2nd Thalassemia Study

by Zacks Equity Research

Data from a late-stage study shows that transfusion-dependent thalassemia patients who received Agios' (AGIO) Pyrukynd demonstrated a statistically significant reduction in transfusion burden.

Agios (AGIO) Up 23% on Selling Brain Cancer Drug Royalty

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) agrees to sell to Royalty Pharma the rights to royalties on potential net sales of a brain cancer drug that was sold to Servier in 2021.

Are Medical Stocks Lagging Lantheus (LNTH) This Year?

by Zacks Equity Research

Here is how Lantheus Holdings (LNTH) and Agios Pharmaceuticals (AGIO) have performed compared to their sector so far this year.

How Much Upside is Left in Agios Pharmaceuticals (AGIO)? Wall Street Analysts Think 26.43%

by Zacks Equity Research

The mean of analysts' price targets for Agios Pharmaceuticals (AGIO) points to a 26.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 26.01% Upside in Agios Pharmaceuticals (AGIO): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 26% upside potential for Agios Pharmaceuticals (AGIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates

by Zacks Equity Research

Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.

Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 11.59% and 2.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates

by Zacks Equity Research

Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.

Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -4.88% and 9.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stock Q4 Earnings Due on Feb 15: ALNY, BPMC & More

by Zacks Equity Research

Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15.

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.